An scRNA-seq analysis of 16,291 immune cells isolated from 48 melanoma patients treated with ICB immunotherapy showed that the tumor-infiltrating CD8+ T cells of these patients exhibited distinctive phenotypes. This evidence concerns the gene CD8A and neoplasm.